

Special Issue

Gene Therapy with Emphasis on RNA Interference

Message from the Guest Editor

The progress in gene therapy has been hampered by delivery inefficacy and safety concerns. Recent progress has casted some promising light on future development. A number of viral vectors have been re-engineered for improved delivery and enhanced safety. In this context, adenovirus, adeno-associated virus, lentivirus, retroviruses and other virus vectors have provided therapeutic efficacy for various diseases such as severe combined immunodeficiency, hemophilia, cancer and infectious diseases. The discovery of RNA interference, particularly the use of short interfering RNA and micro-RNA for reversible gene silencing, has substantially widened the application range of gene therapy. In this Special Issue, applications of various viral vectors and their use in gene therapy are reviewed with a special emphasis on RNA interference.

Guest Editor

Dr. Kenneth Lundstrom
PanTherapeutics, Rue des Remparts 4, CH-1095 Lutry, Switzerland

Deadline for manuscript submissions

closed (28 February 2015)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.8
CiteScore 7.3
Indexed in PubMed



mdpi.com/si/3723

Viruses
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.8
CiteScore 7.3
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

Director, HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2024).